Angiex
PrivateLast Round
VC Round
Nov 17, 2025
Total Funding Raised
$48.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Angiex operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a VC Round in November 2025.
Angiex is a biopharmaceutical company that develops vascular-targeted biotherapeutics and nuclear-delivered antibody-drug conjugates for the treatment of solid cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Angiex Comparables
Compare Angiex with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BiOneCure Therapeutics, Inc. | 86% | |
| Adcendo | 85% | |
| Adcentrx Therapeutics | 85% |
For institutional investors. Book with your work email.
Angiex Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Nov 17, 2025 | ||||
| Series B | Aug 18, 2021 | ||||
| Seed | Jul 27, 2017 | ||||
| Grant | Nov 2, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Angiex Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gaingels | Seed |
| Paulson Investment Company | VC Round |
| Presight Capital | Series B |
| Starling Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 296% MoM, from 652 to 2.6K.
- Apr 17, 2026
Presented in vivo data for AGX101, a cancer therapy candidate.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 27, 2026
On Aug 27th '26, Angiex expands clinical development of investigational AGX101 through a collaboration with Natera that adds longitudinal Signatera ctDNA testing to an ongoing Phase I trial in patients with advanced solid tumors.
For institutional investors. Book with your work email.
Angiex Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Angiex's valuation, stock price, and market status.
Is Angiex a public or private company?
Angiex is a private company.
What is the current stock price of Angiex?
Angiex is a private company, so its shares have no public market price. Caplight tracks Angiex's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Angiex worth (valuation)?
Valuation information for Angiex is not publicly available.
Can I buy Angiex stock?
Angiex shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Angiex's last funding round?
Angiex's most recent funding round was VC Round on November 17, 2025.
Who are the main investors in Angiex?
Key investors in Angiex include Presight Capital.
Will Angiex IPO soon?
No public IPO plans have been announced for Angiex.
How can I track Angiex secondary market activity?
Caplight tracks bids, offers, and trades in Angiex's shares on secondary markets.